WO2004046101A3 - Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors - Google Patents

Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors Download PDF

Info

Publication number
WO2004046101A3
WO2004046101A3 PCT/US2003/035670 US0335670W WO2004046101A3 WO 2004046101 A3 WO2004046101 A3 WO 2004046101A3 US 0335670 W US0335670 W US 0335670W WO 2004046101 A3 WO2004046101 A3 WO 2004046101A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyanoamidines
cyanoguanidines
erbb2
egfr inhibitors
treatment
Prior art date
Application number
PCT/US2003/035670
Other languages
French (fr)
Other versions
WO2004046101A2 (en
Inventor
Eli Wallace
George Topalov
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority to EP03768789A priority Critical patent/EP1567506A4/en
Priority to CA002506503A priority patent/CA2506503A1/en
Priority to JP2004553551A priority patent/JP4611745B2/en
Priority to AU2003291394A priority patent/AU2003291394B2/en
Priority to MXPA05005370A priority patent/MXPA05005370A/en
Priority to NZ540092A priority patent/NZ540092A/en
Publication of WO2004046101A2 publication Critical patent/WO2004046101A2/en
Publication of WO2004046101A3 publication Critical patent/WO2004046101A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Use of the compounds of the invention to manufacture therapeutic compositions for the treatment of hyperproliferative diseases in mammals is also disclosed.
PCT/US2003/035670 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors WO2004046101A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03768789A EP1567506A4 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
CA002506503A CA2506503A1 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
JP2004553551A JP4611745B2 (en) 2002-11-20 2003-11-10 Cyanoguanidine and cyanoamidine as ErbB2 and EGFR inhibitors
AU2003291394A AU2003291394B2 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
MXPA05005370A MXPA05005370A (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors.
NZ540092A NZ540092A (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42754402P 2002-11-20 2002-11-20
US60/427,544 2002-11-20

Publications (2)

Publication Number Publication Date
WO2004046101A2 WO2004046101A2 (en) 2004-06-03
WO2004046101A3 true WO2004046101A3 (en) 2004-09-16

Family

ID=32326558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035670 WO2004046101A2 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors

Country Status (6)

Country Link
EP (1) EP1567506A4 (en)
JP (1) JP4611745B2 (en)
AU (1) AU2003291394B2 (en)
CA (1) CA2506503A1 (en)
NZ (1) NZ540092A (en)
WO (1) WO2004046101A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
KR20060037447A (en) * 2003-08-18 2006-05-03 화이자 프로덕츠 인크. Dosing schedule for erbb2 anticancer agents
EP1673110A2 (en) * 2003-09-11 2006-06-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy
US7659284B2 (en) 2004-09-15 2010-02-09 Janssen Pharmaceutica Nv Thiazolopyridine kinase inhibitors
WO2006118749A1 (en) 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
DE102006012251A1 (en) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments
US7851623B2 (en) 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
WO2009057139A2 (en) 2007-10-29 2009-05-07 Natco Pharma Limited Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
WO2011002523A1 (en) 2009-07-02 2011-01-06 Kanionusa Inc. Phosphorus containing quinazoline compounds and methods of use
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (en) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Therapeutic compounds and their uses
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108285421A (en) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 A kind of method of micro passage reaction synthesis lapatinib intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184225B1 (en) * 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163546B1 (en) * 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6423716B1 (en) 1998-03-31 2002-07-23 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EA005525B1 (en) 2000-06-22 2005-04-28 Пфайзер Продактс Инк. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184225B1 (en) * 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1567506A4 *

Also Published As

Publication number Publication date
AU2003291394A1 (en) 2004-06-15
EP1567506A2 (en) 2005-08-31
CA2506503A1 (en) 2004-06-03
EP1567506A4 (en) 2007-06-20
AU2003291394B2 (en) 2009-06-25
NZ540092A (en) 2007-06-29
JP2006508979A (en) 2006-03-16
JP4611745B2 (en) 2011-01-12
WO2004046101A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004046101A3 (en) Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2005048948A3 (en) Urea derivatives as kinase modulators
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
WO2003088808A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004030620A3 (en) Novel tyrosine kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2506503

Country of ref document: CA

Ref document number: 540092

Country of ref document: NZ

Ref document number: 2003291394

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005370

Country of ref document: MX

Ref document number: 2004553551

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003768789

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003768789

Country of ref document: EP